MiR-374a by targeting CCND1could retard G1/S transition and suppress cell growth, metastasis, and sensitize NPC cells to cisplatin via PI3K/Akt signaling pathway. The gene discussed is AKT1; the disease is nasopharyngeal carcinoma.